Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for COVID-19 and other severe lung infections. UK-based and AIM listed, we were founded in 2003 as a spin-out from the University of Southampton.
SNG001 is a host-directed, broad-spectrum antiviral that directly targets the site of infection - the lungs. Its mode of action does not depend on a particular virus or variant.
vaccination programmes and the availability of new therapeutics,
thousands of patients are being hospitalised with COVID-19 every day.
There is an urgent clinical need for new therapies to prevent the worsening of the disease, accelerate hospital discharge and
enable patients to quickly return to usual activities.
Results from the Phase 3 SPRINTER trial of SNG001 in hospitalised COVID-19 patients were announced in February 2022. SNG001 is currently being evaluated as part of the Phase 2 US NIH ACTIV-2 trial in home-based COVID-19 patients and, in October 2021, was recommended to advance into that trial’s larger follow-on Phase 3 study in mild to moderate COVID-19 patients. Positive Phase 2 data, published in the Lancet Respiratory Medicine in 2020, established proof of principle for SNG001 in COVID-19.